Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ultragenyx Pharmaceutical's current ratio for the quarter that ended in Mar. 2026 was 2.02.
Ultragenyx Pharmaceutical has a current ratio of 2.02. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ultragenyx Pharmaceutical's Current Ratio or its related term are showing as below:
MEX:RARE'
s Current Ratio Range Over the Past 10 Years
Min: 1.89 Med: 4.5 Max: 12.85
Current: 2.02
During the past 13 years, Ultragenyx Pharmaceutical's highest Current Ratio was 12.85. The lowest was 1.89. And the median was 4.50.
MEX:RARE's Current Ratio is ranked worse than 68.18% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs MEX:RARE: 2.02
Ultragenyx Pharmaceutical (MEX:RARE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ultragenyx Pharmaceutical Current Ratio Related Terms
Ultragenyx Pharmaceutical Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RARE vs VERA, IRON, QURE: Current Ratio Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (MEX:RARE) has a Current Ratio of 2.02 as of Mar. 2026. This is 55% below median its historical median of 4.50. Over the past decade, Ultragenyx Pharmaceutical's Current Ratio has ranged from 1.89 to 12.85. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #962 out of 1411 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Ultragenyx Pharmaceutical's Current Ratio too high?
Ultragenyx Pharmaceutical's current Current Ratio of 2.02 is 55% below median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 12.85. The Biotechnology industry median Current Ratio is 3.88. Ultragenyx Pharmaceutical's value of 2.02 is 47.9% below this industry median. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #962 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Current Ratio compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #962 out of 1411 companies for Current Ratio. This places Ultragenyx Pharmaceutical in the lower half of its industry. The industry median Current Ratio is 3.88. Ultragenyx Pharmaceutical's value of 2.02 is 47.9% below this benchmark. Historically, Ultragenyx Pharmaceutical's own Current Ratio has ranged from 1.89 to 12.85 over the past decade. While the company's 10-year median is 4.50 vs. the industry median of 3.88, Ultragenyx Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragenyx Pharmaceutical's current Current Ratio of 2.02 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current Current Ratio is 2.02, which is 55% below median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Current Ratio of 2.02. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Current Ratio is 2.02, which is 55% below median its 10-year median of 4.50 and 47.9% below the Biotechnology industry median of 3.88. Ultragenyx Pharmaceutical's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Current Ratio is 2.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.
Key valuation signals for MEX:RARE:
Current Ratio: 2.02 (55% below median its 10-year median of 4.50)
GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
Industry Position: 47.9% below the Biotechnology median (#962 of 1411)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score
Get the complete analysis for MEX:RARE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
